Trials / Completed
CompletedNCT00311363
Long-Term Study of Gabapentin Enacarbil (GEn, XP13512) vs. Placebo in Patients With Restless Legs Syndrome.
A Long-Term Study of XP13512 Versus Placebo Treatment Assessing Maintenance of Efficacy and Safety in Patients With Restless Legs Syndrome.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 327 (actual)
- Sponsor
- XenoPort, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this trial is to assess the maintenance of efficacy of gabapentin enacarbil (GEn, XP13512) taken once daily in the long-term treatment of patients suffering from Restless Legs Syndrome (RLS).
Detailed description
This study was a multicenter, blinded, randomized withdrawal study in subjects with primary Restless Legs Syndrome (RLS). Eligible subjects were initially enrolled in a 24-week single blind (SB) treatment period during which they received XP13512. Subjects who completed the initial treatment period and met the responder criteria were then randomized 1:1 to receive either XP13512 or placebo during the 12-week double-blind (DB) treatment period. The primary study objective was to assess the maintenance of efficacy of XP13512 1200 mg taken once daily in the long-term treatment of subjects with primary RLS. The secondary study objectives were to assess maintenance of improvements in sleep outcomes and quality of life, and to assess the safety and tolerability of XP13512 in the treatment of primary RLS subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GEn (XP13512) | 1200 mg GEn (XP13512) orally, once daily for 24 weeks followed by either 1200 mg GEn (XP13512) or placebo, orally, once daily for an additional 12 weeks |
| DRUG | GEn (XP13512) | 1200 mg GEn (XP13512), orally, once daily for 24 weeks followed by either 1200 mg GEn (XP13512) or placebo, orally, once daily for an additional 12 weeks |
| DRUG | Placebo | Placebo, orally, once daily for 12 weeks following single blind 24-week phase |
Timeline
- Start date
- 2006-04-01
- Primary completion
- 2007-11-01
- Completion
- 2007-11-01
- First posted
- 2006-04-05
- Last updated
- 2013-07-22
- Results posted
- 2011-05-25
Source: ClinicalTrials.gov record NCT00311363. Inclusion in this directory is not an endorsement.